Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy.

A clinical trial, NCT06522581, is investigating the use of citicoline as a neuroprotector in neonates with moderate and severe hypoxic ischemic encephalopathy (HIE). HIE is a brain injury caused by asphyxia in newborns, resulting in mortality and long-term morbidity. Current treatments are not effective, and therapeutic hypothermia, the only effective neuroprotector, has limited applicability. Citicoline, a new neuroprotector, has shown promise in regenerating neuronal cells and inhibiting the ischemic cascade. The trial aims to explore safe, effective, and accessible neuroprotective therapies, particularly in developing countries. The article also provides a brief overview of a research report on choline, its potential risks, and prevention methods, without expressing any judgments or opinions. [Extracted from the article]